MercoPress. South Atlantic News Agency

Pfizer and BioNTech anticipate 2 million doses for Uruguay during 2021

“We feel deeply honored to work with the Uruguayan government and to guide our scientific and production resources towards our common objective”, said Carlos Murillo from Pfizer

Pfizer Uruguay and BioNTech SE said in a release that Uruguay will be receiving 2,700,00 doses of the BNT162b2 vaccine, based on ARNm, against the SARS-CoV-2 and delivery will take place “progressively during 2021”

 At midday Saturday Uruguayan president Luis Lacalle Pou had anticipated that the arrival of the first 200,000 doses of the Pfizer vaccine is “expected at the start of March”, and “we don't discard the possibility this could happen at the end of February” .

“We feel deeply honored to work with the Uruguayan government and to guide our scientific and production resources towards our common objective, providing the Uruguayans with a vaccine against the Covid 19, as quick as possible”, Carlos Murillo, Pfizer regional president for Latin America said.

“Given this world sanitary emergency, the purpose of Pfizer has acquired a greater urgency. Our hopes are that our vaccine helps to make this possible”, added Murillo.

Sean Marett, head of Business, and Commercial Director of the German lab BioNTech said he would like to thank the Uruguayan government “for its support and for trusting in our capacity to develop a vaccine, which we believe has the potential to help face the global threat of this pandemic. Our objective continues to be to maintain a global supply of a vaccine against Covid 19, which is safe and efficient for many people in all the world, at the fastest time possible”.

The US and German labs also reported that Phase 3 for the clinic study of BNT162b2, based in ARNm technology from BioNTech, “was launched last 27 July and has enrolled approximately 44,000 participants from the US, Germany, Turkey, South Africa, Brazil and Argentina. Likewise ”all participants will continue to be monitored for the long term protection and safety during a two year additional period following the second doses.